Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-0.20%
SPX
-0.64%
IXIC
-1.15%
FTSE
-0.32%
N225
-1.82%
AXJO
-0.40%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Latest Corcept Therapeutics News

benzinga.com

Witnessing An Insider Decision, Gary Charles Robb Exercises Options Valued At $328K At Corcept Therapeutics

4 days ago
benzinga.com

A Look at Axsome Therapeutics's Upcoming Earnings Report

about 1 month ago
benzinga.com

A Glimpse of Teva Pharmaceutical Indus's Earnings Potential

about 1 month ago
benzinga.com

What's Driving the Market Sentiment Around Corcept Therapeutics?

about 2 months ago
benzinga.com

Insider Decision: Gary Charles Robb Offloads $225K Worth Of Corcept Therapeutics Stock

2 months ago
benzinga.com

Major Update: LEONARD BAKER JR At Corcept Therapeutics Exercises Options, Realizing $0

3 months ago
businesswire.com

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call

Feature Image for interests on Healthcare, Stock from businesswire.com
7 months ago
businesswire.com

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

Feature Image for interests on Healthcare, Stock from businesswire.com
8 months ago
businesswire.com

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes

Feature Image for interests on Healthcare, Stock, Technology from businesswire.com
9 months ago
businesswire.com

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes

Feature Image for interests on Healthcare, Stock, Technology from businesswire.com
9 months ago
Stocks
Health Care
cort
Corcept Therapeutics
NASDAQ: CORT
+0.15 (+0.21%)
69.73
USD
At close at Aug 29, 20:39 UTC
Summary
News
Signals
Benchmarks
Financials

Latest Cashu News

publisher logo
Cashu

Corcept Therapeutics' Leadership Moves Signal Confidence in Future Growth and Strategic Direction

3 days ago
publisher logo
Cashu

Corcept Therapeutics: Executive Confidence and Commitment to Growth Through Stock Options Exercise

5 days ago
publisher logo
Cashu

Corcept Therapeutics: Leading Innovations in CNS Disorder Treatments and Patient Advocacy

28 days ago